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MEMBRANE-PERMEABLE PEPTIDE 
CAPABLE OF CALPAIN INHIBITION 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims priority to provisional application 
60/438,318, ?led Jan. 7, 2003. 
FIELD OF THE INVENTION 
The invention pertains to peptides that are membrane 
permeable and effective at protecting neurons against 
calpain-mediated cell death. In particular, the peptides of the 
invention are similar to domains A and C of calpastatin, 
Which is a knoWn inhibitor of calpain I and calpain II. 
However, unlike calpastatin, the peptides of the invention do 
not target an active cysteine of calpain. 
BACKGROUND OF THE INVENTION 
Calpain is a cytosolic calcium-dependent cysteine pro 
tease. It is found in all mammalian tissue and cell types. The 
calpain family of proteases consists of tWo recognized 
proteins. 
The ?rst member of the calpain family is calpain I or 
u-calpain Which is the high sensitivity form and is activated 
by a loW calcium concentration (2-75 uM). Calpain I is 
concentrated in synapses and neuronal cell bodies. 
The second member of the calpain family is calpain II or 
m-calpain. It has a ribbon like structure and is the loWer 
sensitivity form. It is activated by higher concentrations of 
calcium (200-800 uM). Calpain II is the dominant form. 
Calpastatin is a knoWn endogenous inhibitor of calpain I 
and calpain II. It has four internally repeated domains, each 
of Which independently binds a calpain molecule in its 
active, Ca++-bound conformation With high a?inity. 
Calpains play an important role in various physiological 
processes. These processes include, inter alia, the cleavage 
of regulatory proteins such as protein kinase C (PKC) and 
degradation of cytoskeletal or microtubule-associated pro 
teins (MAP) such as tau. Research has demonstrated that 
calpain inhibitors have improved recovery from the memory 
performance de?cits and neuromotor disturbances. Calpain 
inhibitors inhibit the release of the l3-AP4 protein. There 
fore, it has been suggested that they have a potential use as 
therapeutic agents in AlZheimer’s disease. Calpain inhibitors 
have also had a protective effect on hypoxia-damaged kid 
neys and have had favorable effects folloWing cardiac dam 
age produced by ischemias of the heart (e.g., myocardial 
infarction) or reperfusion. It has also been found that calpain 
inhibitors have cytotoxic effects on tumor cells. Elevated 
calpain levels are also implicated in the pathophysiology of 
cerebral ischemia, platelet activation, NF-KB activation, 
muscular dystrophy, cataract progression and rheumatoid 
arthritis. With various pathophysiological processes such as, 
in?ammations, muscular dystrophies, cataracts of the eyes, 
and injuries to the central nervous system (e.g., trauma). 
Calpains reside in the cytosol of cells and are activated by 
Ca++ at a physiological pH. Its proteolytic activity appears to 
be selective against certain target proteins, such as compo 
nents of the cytoskeleton and calmodulin-dependent 
enzymes. 
Excessive excitation by a neurotransmitter glutamate can 
lead to death of nerve cells (neurons) and neurodegenera 
tion. It is believed that toxic effects of glutamate comes from 
overactivation of its target glutamate receptors (e.g., under 
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ischemic conditions or stroke). This in turn produces an 
in?ux of calcium ion (Ca++) into the neurons. The rise of 
cellular Ca++ level triggers the activation of calpain I. 
Calpain I then goes on to degrade cytoskeletal protein such 
as spectrin, Which is believed to disrupt normal cellular 
functions, and eventually leads to cell death. 
SUMMARY OF THE INVENTION 
The invention is directed to proteins and methods of using 
the proteins that inhibit calpains I and II. The method 
includes contacting the cell With an effective amount of the 
protein for inhibiting calpains I and II. 
In one aspect of the invention there is provided a peptide 
comprising an amino acid sequence (Leu or Ala)-Q(aa)-(Asp 
or Glu)-(Xaa)-(Leu or Met), Where Xaa is any amino acid 
(SEQ ID NO:2). In a preferred embodiment the peptide has 
the amino acid sequence, Leu-Ser-Glu-Ala-Leu (LSEAL). 
In a another aspect of the invention there is provided a 
method for inhibiting calpain comprising contacting a cell 
With an amount of a peptide comprising the amino acid 
sequence (Leu or Ala)-Q(aa)-(Asp or Glu)-(Xaa)-(Leu or 
Met), Where Xaa is any amino acid (SEQ ID NO:2). 
In yet another aspect of the invention there is provided a 
method for inhibiting calpain-dependent cell death compris 
ing contacting a cell With an effective amount of a cell 
membrane permeable peptide comprising the sequence (Leu 
or Ala)-(Xaa)-Asp or Glu)-(Xaa)-(Leu or Met), Where Xaa 
is any amino acid (SEQ ID NO:2). 
The invention also provides a method for protecting cells 
from UV irradiation-induced cell death comprising exposing 
the cells to an effective amount of a polypeptide having the 
amino acid sequence, (Leu or Ala)-(Xaa)-(Asp or Glu) 
Q(aa)-(Leu or Met), Where Xaa is any amino acid (SEQ ID 
NO:2). 
Other objects, features and advantages of this invention 
Will become apparent upon reading the folloWing detailed 
description and referring to the accompanying draWings. 
BRIEF DESCRIPTION OF THE DRAWINGS 
A more complete appreciation of the invention and many 
of the attendant advantages thereof Will be readily obtained 
as the same become better understood by reference to the 
folloWing detailed description When considered in connec 
tion With the accompanying draWings. 
FIG. 1 is a graphical illustration of the relationship of dose 
response of Leu-Ser-Glu-Ala-Leu (LSEAL) (SEQ ID NO. 
3) With ionomycin (ionomycin toxicity) With respect to cell 
death. 
FIG. 2 is a plot of the relationship of ultraviolet light (UV) 
exposure and cell death betWeen cultured Samples of cor 
tical neurons containing no LSEAL and Samples containing 
LSEAL. 
FIG. 3 is a plot of the relationship of the effect of LSEAL 
on tau degradation by calpain I. 
DETAILED DESCRIPTION OF THE 
INVENTION 
This invention relates to 5-mer peptides and methods of 
using these peptides for inhibiting calpain. In particular, the 
peptides comprise the folloWing sequence: (Leu or Ala) 
Q(aa)-(Asp or Glu)-(Xaa)-(Leu or Met), Where Xaa can be 
any amino acid (SEQ ID NO. 2). 
In one embodiment, Xaa is selected from the group 
consisting of Ala, Arg, Ile, Leu, Pro, Phe, Ser, Thr and Tyr. 
US 7,385,027 B2 
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In another embodiment, the peptides include Leu-Ser-Glu 
Ala-Leu (SEQ ID NO:3), Leu-Ala-Asp-Ala-Leu (SEQ ID 
NO:4), Leu-Phe-Glu-Ala-Leu (SEQ ID NO:5), Leu-Tyr 
Asp-Ala-Leu (SEQ ID NO:6), Leu-Leu-Glu-Ala-Leu (SEQ 
ID NO:7), Leu-Arg-Asp-Ala-Leu (SEQ ID NO:8), Leu-Tyr 
Asp-Ala-Met (SEQ ID NO:9), Leu-Thr-Asp-Ala-Leu (SEQ 
ID NOzlO), Ala-Leu-Asp-Ala-Leu (SEQ ID NOzll), Leu 
Leu-Asp-Ala-Leu (SEQ ID NO: 12), Pro-Ile-Asp-Ala-Leu 
(SEQ ID NOzl3) Leu-Ile-Asp-Glu-Leu (SEQ ID NOzl4), 
Ala-Ile-Asp-Ala-Leu (SEQ ID NOzl5), Leu-Ile-Asp-Thr 
Leu (SEQ ID NOzl6), Leu-Ala-Asp-Ser-Leu (SEQ ID 
NOzl7), and Leu-Ser-Asp-Ser-Leu (SEQ ID NOzl8). All of 
these amino acid sequences are similar to the binding region 
of the endogenous inhibitor calpastatin. 
One particular ?ve amino acid peptide comprising Leu 
Ser-Glu-Ala-Leu (SEQ ID NO. 3) (hereinafter LSEAL is 
particularly preferred for its ability to inhibit calpain activity 
both in vitro and in situ. It Was found that this peptide is 
membrane-permeable and effective at protecting neurons 
against calpain-mediated cell death in two different para 
digms. 
LSEAL is similar to domains Aand C of calpastatin Which 
have been extensively studied by others in Which they have 
shoWn that regions of calpastatin that are similar to our 
peptides are required for full inhibition of calpains. In 
addition, other groups have shoWn that mutations of speci?c 
amino acids in domains A or C, Which are the equivalent 
amino acids in our peptide (SEQ ID NO. 3) of the present 
invention, result in reduced calpastatin inhibitory action, 
indicating that the sequence is likely optimal for calpain 
inhibition. These ?ndings suggest that the peptides of the 
invention can mimic the actions of calpastatin. 
The LSEAL peptide inhibits calpain activity in vitro 
toWards the substrate tau protein. Also, this peptide prevents 
calpain-dependent cell death in tWo model systems of loW 
dose ionomycin treatment as Well as UV-induced cell tox 
icity. While other synthetic inhibitors are available for 
calpains, this peptide has several advantages. 
First, all other calpain inhibitors target the active site 
cysteine of calpain. This leads to signi?cant speci?city loss 
as many other proteases have cysteine residues at their 
active sites that have been shoWn to be modi?ed by these 
other inhibitors. As such, it is extremely unlikely that the 
peptides Will react With other proteases. The peptides of the 
invention mimics a key portion of the calpastatin molecule 
required for its endogenous and speci?c inhibitory action to 
the calpains. 
Second, the peptides of the invention are membrane 
permeable Without the need for other modi?cations. The 
peptides of the present invention can affect changes inside a 
cell, and are likely to produce more speci?c effects due to 
calpain, and are more membrane-permeable than all previ 
ous calpain inhibitors. 
The description beloW sets forth the method used to 
identify the peptide(s) using the PhD-l2TM phage display 
system from NeW England Biolabs (NEB). The protocol for 
determining the number of phages is from the NEB Ph.D 
l2TM Kit manual, version 2.5. In this method, the active-site 
of calpain I Was irreversibly inactivated or blocked With 
Calpain Inhibitor IV, and the peptide(s) Were isolated as 
calcium-dependent binding peptides. Therefore, these pep 
tides have a calpain I conformation-dependent binding 
sequence. 
A mixture of 500 pL of Hepes balanced salt solution 
(HBSS) (2>< concentration) Was mixed With 475 pL distilled 
Water, 20 pL of calpain I, 0.5 pL of calpain inhibitor IV and 
5 pL of 200 mM CaCl2. Calpain inhibitor IV Was in a bulfer 
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containing 20 mM Hepes, 0.7 mM Na2HPO4, 137 mM 
NaCl, 5 mM KCl, 6 mM glucose at a pH 7.4 (l><HBSS) in 
the presence of 1 mM CaCl2. The calpain inhibitor IV Was 
added to permanently block the active cysteine of calpain I. 
CaCl2 Was added to activate the calpain I active site. A single 
Well of a Nunc-ImmunoTM microWell plate With a Max 
iSorpTM surface Was ?lled With 200 pL of the mixture and 
incubated at room temperature for 15 minutes. The plate Was 
covered and shaken in an orbital shaker for 30 minutes at 370 
C. and at 250 rpm. 
The Well Was rinsed three times With a rinse solution 
comprising l>< concentration of HBSS and 1 mM CaCl2 to 
remove excess and/ or non-bound calpain I. To prevent direct 
binding of the phage to the Sample Well, the Well and a 
second Well (hereinafter a control Well) Were treated With a 
blocking agent, a 3% bovine serum albumin (BSA) in 
l><HBSS in 1 mM CaCl2. The plate Was then covered and 
shaken in the orbital shaker for 30 minutes at 370 C. and at 
250 rpm. The control Well and the Sample Well Were then 
rinsed three times With the rinse solution. 
The phage (approximately 2><l0ll cells) Were added to the 
control Well. The plate Was covered and shaken in the orbital 
shaker for 30 minutes at 370 C. and at 250 rpm. The phage 
Were then transferred to the Sample Well containing calpain 
I and the plate Was covered and shaken in the orbital shaker 
for 30 minutes at 370 C. and at 250 rpm. After incubation, 
the plate Was Washed 50 times With the rinse solution to 
remove excess or non-bound phage. The ?nal Wash, i.e., the 
50th Wash, Was saved and placed in a microtube. 
In accordance With the protocol in the NEB instruction 
manual, the Sample Well Was eluted four times With HBSS 
and 1 mM ethyleneglycol-bis([3-aminoethylether)-N,N,N', 
N'-tetraacetic acid (EGTA), a calcium chelating agent. Each 
elution With EGTA Was for a period of 10 to 15 minutes at 
room temperature and 60 rpm shaking. Each of the four 
elutions Were saved. The Well Was then eluted With a 
solution containing 0.2 M glycine having a pH of 2.2, and 
then With 4M solution of urea. As for the elution With 
glycine, this step Was performed for 5 minutes at room 
temperature folloWed by a neutraliZation step by adding 150 
pL of 1M tris-HCl to raise the pH to 9.1 to prevent killing 
of the phage. The glycine and urea elutants Were combined. 
Each elutant, including the saved ?nal Wash Was titered to 
measure the number of phage remaining in the elutant. 
Ampli?ed phage Were then titred to determine their 
concentration and the process Was repeated four times using 
the ampli?ed phage from the previous round. The phage 
from the ?nal screening process Were sequenced to deter 
mine a consensus binding sequence. The titre results Were as 
folloWs: 
Round 1 (x103): Final Wash:l00; Elution 1:800; Elution 
2:615; Elution 3:411; Elution 4:362; Glycine/Urea com 
bination:l00. 
Round 2 (x102): Final Wash:2; Elution l:l400; Elution 
3:120; Elution 4:38; Glycine/Urea:75. 
Round 3 (x103): Final Wash:7; Elution l:l4,l30; Elution 
2:5495; Elution 3Il800; Elution 4:l570; Glycine/ 
Urea:3l40. 
Round 4 Was not titred. 
In order to demonstrate the effectiveness of the inhibition 
of calpain by the peptides of this invention, tWo in situ 
experiments Were conducted using cultured cortical neurons 
from rat brains to shoW that the LSEAL peptide inhibited 
cell death. In the ?rst experiment, cell death of the neurons 
Was induced by exposing the culture to ionomycin. In the 
second experiment, cell death Was induced by exposing the 
neurons to 30 and 60 mJ/cm2 of UV light. The exposure to 
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either ionomycin or UV light caused calpain I to be activated 
because of ionomycin-mediated calcium ?ux or through 
UV-induced receptors, channels or pore-like structures. Cal 
cein acetoxymethyl ester Was used as indicator of live 
neuron cells While propidium iodide Was used an indicator 
of dead neuron cells. 
In the ?rst experiment, ten Samples Were prepared. 
Sample 1 Was a control Sample and included the cultured 
cortical neurons only. A baseline for the average percentage 
ofcell death Was determined to be 19%. In Sample 2, 0.4 uM 
ionomycin Was added to the cultured neuron cells to activate 
calpain I. No LSEAL Was added to these Samples. The 
addition of ionomycin to these Samples caused the percent 
age of dead cells to more than triple to an average of 68%. 
Sample 3 Was the same as Sample 2 except that 0.00001 
micromolar of LSEAL Was added before the ionomycin Was 
added. The percentage of dead cells averaged of 106% of no 
LSEAL. Sample 4 Was the same as Sample 3 except that 
0.0001 micromolar of LSEAL Was added. The percentage of 
cell death Was 83% of no LSEAL. Sample 5 Was the same 
as Sample 4 except that 0.001 micromolar LSEAL Was 
added. The percentage of cell death Was 63% of no LSEAL. 
Sample 6 Was the same as Sample 5 except that 0.01 
micromolar LSEAL Was added. The percentage of cell death 
Was 61% of no LSEAL. Sample 7 Was the same as Sample 
6 except that 0.1 micromolar LSEAL Was added. The 
percentage of cell death Was 57% of no LSEAL. Sample 8 
Was the same as Sample 7 except that 1.0 micromolar 
LSEAL Was added. The percentage of cell death Was 48% of 
no LSEAL. Sample 9 Was the same as Sample 8 except that 
10.0 micromolar LSEAL Was added. The percentage of cell 
death Was 35% of no LSEAL. Sample 10 Was the same as 
Sample 9 except that 100 micromolar LSEAL Was added. 
The percentage of cell death Was 33% of no LSEAL. It is 
clear from this experiment that the peptide of the invention 
inhibited calpain I activity. The results are summariZed in 
Table 1 beloW and the results are graphically illustrated in 
FIG. 1 
TABLE 1 
Percentage 
Average cell 
death Number 
(ratioed to 0 Standard Error of Samples Percent 
Micromolar LSEAL) of the Mean (n =) (raW data) 
0 LSEAL 100 4.8 13 
(Sample 2) 
.00001 106 13.0 13 
LSEAL 
(Sample 3) 
.0001 83 10.7 3 
LSEAL 
(Sample 4) 
.001 LSEAL 63 14.2 4 
(Sample 5) 
0.01 LSEAL 61 9.4 5 
(Sample 6) 
0.1 LSEAL 57 5.9 7 
(Sample 7) 
1 LSEAL 48 4.9 4 
(Sample 8) 
10 LSEAL 35 3.3 6 
(Sample 9) 
100 LSEAL 33 8.0 3 
(Sample 10) 
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TABLE 1-continued 
Percentage 
Average cell 
death 
(ratioed to 0 
LSEAL) 
Number 
of Samples 
(11 =) 
Standard Error 
of the Mean 
Percent 
Micromolar (raW data) 
Cell death 
percentages 
raW data: 
Control 19 
(vehicle 
treatment 
only) — 
Sample 1 
lonomycin 
alone — 
Sample 2 
68 
In the second experiment, cell death of the cultured 
cortical neurons Was induced by UV light. Samples 11, 12 
and 13 Were control Samples Which did not contain any 
LSEAL. Sample 11 shoWs the normal % dead cells With no 
exposure to UV light. The percentage of cell death Was 18%. 
Sample 14 is the same as Sample 11, except for the addition 
of 100 uM LSEAL to the culture. The percentage of cell 
death Was reduced from 18% to 14%. Sample 12 Was 
exposed to 30 mJ/cm2 of UV light. The percentage of cell 
death Was 58%. The inclusion of the LSEAL before expo 
sure reduced the percentage of cell death to 25%. See 
Sample 15. If the exposure is increased to 60 mJ/cm2, the 
cell death percentage is 74% for the culture Which does not 
contain LSEAL (see Sample 13), and 30% for a culture 
containing LSEAL (see Sample 16). The data clearly shoW 
that the peptide of the present invention protects neurons 
from UV-induced, calpain-dependent cell death. The data for 
the experiment is set forth beloW in Tables 3 and 4, and is 
graphically illustrated in FIG. 2. 
TABLE 2 
Sample Live Cells Dead Cells Total Cells % Dead Cells 
11 36 7 43 18 
12 25 33 5 8 58 
13 17 42 59 74 
14 30 5 35 14 
15 78 26 104 25 
16 56 25 81 30 
TABLE 3 
UV Light Live Dead Total % Dead 
Exposure Samples Cells Cells Cells Cells Std Dev 
0 mJ/cm2 11 (Control) 36 7 43 18 10 
14 30 5 35 14 10 
30 mJ/cm2 12 (Control) 25 33 58 58 1 
15 78 26 104 25 2 
60 mJ/cm2 13 (Control) 17 42 59 74 17 
16 56 25 81 30 6 
Another experiment Was conducted to shoW the effect of 
the proteins of the present invention on the tau protein. The 
tau protein is a microtubule-associated protein (MAP). Tau 
is a Well-described calpain I substrate. The addition of 100 
uM LSEAL inhibits degradation of the protein. The results 
are shoWn in FIG. 3. 
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While the salient features have been illustrated and 
described With respect to particular embodiments, it should 
be readily apparent that modi?cations can be made Within 
8 
the spirit and scope of the invention, and it is therefore not 
desired to limit the invention to the exact details shoWn and 
described. 
<l60> NUMBER OF 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
SEQUENCE LISTING 
SEQ ID NOS : l8 
1 
Homo sapiens 
<4 00> SEQUENCE: 1 
Leu Ser Glu Ala Leu 
1 5 
<2ll> LENGTH: 5 
<2l3> ORGANISM: Homo sapiens 
<220> FEATURE: 
<22l> NAME/KEY: MISCiFEATURE 
<222> LOCATION: (1) ..(1) 
<223> OTHER INFORMATION: X is 
<220> FEATURE: 
<22l> NAME/KEY: MISCiFEATURE 
<222> LOCATION: (2) . . (2) 
<223> OTHER INFORMATION: X is 
<220> FEATURE: 
<22l> NAME/KEY: MISCiFEATURE 
<222> LOCATION: (3) . . (3) 
<223> OTHER INFORMATION: X is 
<220> FEATURE: 
<22l> NAME/KEY: MISCiFEATURE 
<222> LOCATION: (4) . . (4) 
<223> OTHER INFORMATION: X is 
<220> FEATURE: 
<22l> NAME/KEY: MISCiFEATURE 
<222> LOCATION: (5) . . (5) 
<223> OTHER INFORMATION: X is 
<400> SEQUENCE: 2 
Xaa Xaa Xaa Xaa Xaa 
l 5 
<2ll> LENGTH: 5 
<2l3> ORGANISM: Homo sapiens 
<400> SEQUENCE: 3 
Leu Ser Glu Ala Leu 
1 5 
<2ll> LENGTH: 5 
<2l3> ORGANISM: Homo sapiens 
<400> SEQUENCE: 4 
Leu Ala Asp Ala Leu 
1 5 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: Homo sapiens 
L or A 
any amino acid 
D or E 
any amino acid 
L or M 
US 7,385,027 B2 
—cont inued 
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<400> SEQUENCE: 
Leu Phe Glu Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Tyr Asp Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Leu Glu Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Arg Asp Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Tyr Asp Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Thr Asp Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Ala Leu Asp Ala 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
5 
Leu 
Homo sapiens 
6 
Leu 
Homo sapiens 
'7 
Leu 
Homo sapiens 
8 
Leu 
Homo sapiens 
9 
Met 
10 
Homo sapiens 
lO 
Leu 
11 
Homo sapiens 
ll 
Leu 
12 
Homo sapiens 
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—cont inued 
12 
Leu Leu Asp Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Pro Ile Asp Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Ile Asp Glu 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Ala Ile Asp Ala 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Ile Asp Thr 
l 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Ala Asp Ser 
1 
<2lO> SEQ ID NO 
<2ll> LENGTH: 5 
<2l2> TYPE: PRT 
<2l3> ORGANISM: 
<400> SEQUENCE: 
Leu Ser Asp Ser 
1 
Leu 
13 
Homo sapiens 
l3 
Leu 
14 
Homo sapiens 
l4 
Leu 
15 
Homo sapiens 
l5 
Leu 
16 
Homo sapiens 
l6 
Leu 
17 
Homo sapiens 
l7 
Leu 
18 
Homo sapiens 
Leu 
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What is claimed is: 
1. An isolated 5-mer peptide selected from the group 
consisting of Leu-Ser-Glu-Ala-Leu (SEQ ID NO:3), Leu 
Ala-Asp-Ala-Leu (SEQ ID NO:4), Leu-Phe-Glu-Ala-Leu 
(SEQ ID NO:5), Leu-Tyr-Asp-Ala-Leu (SEQ ID NO:6), 
Leu-Leu-Glu-Ala-Leu (SEQ ID NO:7), Leu-Arg-Asp-Ala 
Leu (SEQ ID NO:8), Leu-Tyr-Asp-Ala-Met (SEQ ID 
NO:9), Leu-Thr-Asp-Ala-Leu (SEQ ID NOzlO), Ala-Leu 
Asp-Ala-Leu (SEQ D NO: 11), Leu-Leu-Asp-Ala-Leu (SEQ 
ID NOzlZ), Ala-Ile-Asp-Ala-Leu (SEQ ID NO: 15), Leu 
5 
14 
Ile-Asp-Ihr-Leu (SEQ ID NOzl6), Leu-Ala-Asp-Ser-Leu 
(SEQ ID NOzl7), and Leu-Ser-Asp-Ser-Leu (SEQ ID 
NOzl8). 
2. The peptide of claim 1, Wherein the peptide inhibits 
calpain activity towards the substrate tau protein. 
3. An isolated peptide consisting of the sequence Leu 
Ser-Glu-Ala-Leu (SEQ ID NO:3). 
